Serum Afamin a Novel Marker of Increased Hepatic Lipid Content.
Adiposity
Adult
Biomarkers
/ blood
Body Mass Index
Carrier Proteins
/ blood
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
Fatty Liver
/ blood
Female
Follow-Up Studies
Glycoproteins
/ blood
Humans
Insulin Resistance
Lipid Metabolism
Male
Obesity
/ physiopathology
Prediabetic State
/ blood
Prognosis
Serum Albumin, Human
afamin
exercise
hepatic lipids
insulin resistance
prediabetes
type 2 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
02
2021
accepted:
20
08
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Afamin is a liver-produced glycoprotein, a potential early marker of metabolic syndrome. Here we investigated regulation of afamin in a course of the metabolic disease development and in response to 3-month exercise intervention. We measured whole-body insulin sensitivity (euglycemic hyperinsulinemic clamp), glucose tolerance, abdominal adiposity, hepatic lipid content (magnetic resonance imaging/spectroscopy), habitual physical activity (accelerometers) and serum afamin (enzyme-linked immunosorbent assay) in 71 middle-aged men with obesity, prediabetes and newly diagnosed type 2 diabetes. Effects of 3-month exercise were investigated in 22 overweight-to-obese middle-aged individuals (16M/6F). Prediabetes and type 2 diabetes, but not obesity, were associated with increased serum afamin (p<0.001). Afamin correlated positively with hepatic lipids, fatty liver index and liver damage markers; with parameters of adiposity (waist circumference, %body fat, adipocyte diameter) and insulin resistance (fasting insulin, C-peptide, HOMA-IR; p<0.001 all). Moreover, afamin negatively correlated with whole-body insulin sensitivity (M-value/Insulin, p<0.001). Hepatic lipids and fasting insulinemia were the most important predictors of serum afamin, explaining >63% of its variability. Exercise-related changes in afamin were paralleled by reciprocal changes in insulinemia, insulin resistance and visceral adiposity. No significant change in hepatic lipid content was observed. Subjects with prediabetes and type 2 diabetes had the highest serum afamin levels. Afamin was more tightly related to hepatic lipid accumulation, liver damage and insulin resistance than to obesity.
Identifiants
pubmed: 34603196
doi: 10.3389/fendo.2021.670425
pmc: PMC8481912
doi:
Substances chimiques
AFM protein, human
0
Biomarkers
0
Carrier Proteins
0
Glycoproteins
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
670425Informations de copyright
Copyright © 2021 Kurdiova, Balaz, Kovanicova, Zemkova, Kuzma, Belan, Payer, Gasperikova, Dieplinger, Ukropcova and Ukropec.
Déclaration de conflit d'intérêts
Author VB was employed by the company Pro Diagnostic Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
DNA Cell Biol. 2011 Mar;30(3):137-47
pubmed: 20979532
Biochemistry. 2002 Dec 10;41(49):14532-8
pubmed: 12463752
Expert Rev Proteomics. 2020 Jul - Aug;17(7-8):623-632
pubmed: 32921203
J Gastroenterol Hepatol. 2014 Oct;29(10):1839-47
pubmed: 24750217
Reprod Biol Endocrinol. 2014 Sep 10;12:88
pubmed: 25208973
Clin Chim Acta. 2013 Oct 21;425:236-41
pubmed: 23981841
Am J Mens Health. 2017 Nov;11(6):1728-1738
pubmed: 27530821
Cancer Lett. 2000 Nov 28;160(2):229-36
pubmed: 11053653
J Neural Transm Suppl. 2002;(62):337-45
pubmed: 12456077
Diabetes Metab. 2008 Dec;34(6 Pt 2):664-73
pubmed: 19195628
Clin Chim Acta. 2018 Jan;476:160-166
pubmed: 29191735
Diabetes Care. 2007 Mar;30(3):753-9
pubmed: 17327355
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
J Physiol. 2014 Mar 1;592(5):1091-107
pubmed: 24297848
Adv Cancer Res. 1971;14:295-358
pubmed: 4107670
Endocr Connect. 2014 Sep;3(3):120-6
pubmed: 24928911
Diabetes. 2006 May;55(5):1430-5
pubmed: 16644701
J Diabetes Investig. 2020 Sep;11(5):1336-1343
pubmed: 32270583
Diabetes Care. 2017 Oct;40(10):1386-1393
pubmed: 28877915
J Biol Chem. 1994 Jul 8;269(27):18149-54
pubmed: 7517938
Bone. 2012 Sep;51(3):431-40
pubmed: 22749887
Front Endocrinol (Lausanne). 2020 Aug 04;11:495
pubmed: 32849285
Diabetes Res Clin Pract. 2019 Jan;147:37-46
pubmed: 29522788
Curr Opin Lipidol. 2010 Dec;21(6):507-17
pubmed: 21206340
Mol Syst Biol. 2019 Mar 1;15(3):e8793
pubmed: 30824564
Arch Gynecol Obstet. 2018 Nov;298(5):1009-1016
pubmed: 30220025
J Proteome Res. 2005 May-Jun;4(3):889-99
pubmed: 15952736
J Neurochem. 2009 Feb;108(3):707-18
pubmed: 19046407
Endocr Connect. 2019 May 1;8(5):616-624
pubmed: 30991357
Arch Biochem Biophys. 2013 Jan 15;529(2):146-56
pubmed: 23220024
J Biol Chem. 1994 Feb 25;269(8):5481-4
pubmed: 7509788
Reprod Biol Endocrinol. 2018 Mar 27;16(1):30
pubmed: 29587878
Am J Clin Nutr. 1982 Nov;36(5):936-42
pubmed: 7137077
Ann Agric Environ Med. 2018 Sep 25;25(3):527-531
pubmed: 30260179
Circ Cardiovasc Genet. 2014 Dec;7(6):822-9
pubmed: 25176938
PLoS One. 2019 Mar 27;14(3):e0214457
pubmed: 30917176
Placenta. 2018 Feb;62:9-15
pubmed: 29405972
Mol Metab. 2021 Aug;50:101122
pubmed: 33220492